No community oncology practice can do everything alone. Treatments are getting more complex, patient needs are growing, and staying on top of all of it takes more than one practice can manage without outside support. That is why healthcare networks matter. An oncology healthcare network community practice model gives local..
Many cancer patients miss clinical trial opportunities, but the reason is often bigger than a missed search result. A patient may technically match with a trial and still never reach it. The referral may come too late. Records may not move quickly enough. The treating oncologist may not have a..
Ten years ago, a cancer diagnosis often meant one doctor, one clinic, one treatment path. That is not how it works anymore. Today, a single patient might work with half a dozen providers across different locations and specialties. That kind of care can be incredibly effective, but only if everyone..
Cancer data sharing improves cancer research and treatment access by enabling oncologists, clinical investigators, and healthcare institutions to exchange patient information, trial data, and real-world outcomes securely and efficiently, which leads to faster trial enrollment, more accurate treatment decisions, and better patient outcomes across both community and academic care settings…
A healthcare collaboration network connects doctors, specialists, hospitals, and care teams to manage patient treatment together. It works through secure communication, proper referrals, and shared medical updates. It keeps every provider in the loop, cuts down on delays, stops repeated testing, and makes specialist access easier. Platforms like 1104Health are..
Shared Care Networks are helping oncology move from fragmented care toward connected collaboration across academic and local care settings. Key Takeaways The Future of Oncology Care: Why Shared Care Networks Matter Cancer treatment is evolving faster than the systems supporting it. Between cellular therapies, biomarker-driven treatment decisions, bispecific antibodies, antibody-drug..
Introduction Cancer care is becoming more complex every year. New biomarker-driven therapies, cellular therapies, bispecific antibodies, and rapidly expanding clinical trial pipelines are changing how oncologists evaluate and manage treatment options. At the same time, physicians are expected to coordinate increasingly sophisticated care pathways while maintaining continuity, communication, and trusted..
